title: Prevalence and correlates of "high dose" antipsychotic prescribing: findings from a hospital audit.
abstract: BACKGROUND
  High dose antipsychotic prescribing is common in psychiatric care, despite a lack of its benefit from research evidence. While several studies have explored the prevalence and factors associated with high dose antipsychotic prescribing, no such report has emanated from a developing country like Nigeria.
  
  
  OBJECTIVE
  The aims of this study were to determine the prevalence of high dose prescribing among in-patients at a tertiary psychiatric hospital and to determine the pattern of antipsychotic drugs prescribed.
  
  
  METHODS
  An audit of in-patients at a regional tertiary psychiatric facility was carried out. We examined case notes and conducted oral interviews where necessary, on all patients receiving antipsychotics using a proforma designed for the study.
  
  
  RESULTS
  The prevalence of high dose prescribing was 38% (65/171) using a prescribed daily dose/defined daily dose ratio of 1.5. The rate of antipsychotic polypharmacy was 7% (12/171). The atypical antipsychotic, olanzapine was the most commonly prescribed antipsychotic in monotherapy. Predictors of high dose prescribing were diagnoses (P = 0.04), polypharmacy (P = 0.04), a history of previous in-patient care (P = 0.02), and use of anticholinergic drugs (P = 0.01).
  
  
  CONCLUSIONS
  High dose prescribing was common among in-patients audited. Further studies are needed to examine factors that promote "high dose" prescribing.
authors: Department of Clinical Services, Federal Psychiatric Hospital, Benin City, Nigeria.
authors: Ao
authors: A
authors: Adesola
authors: Ig
authors: I
authors: Anozie
authors: P
authors: P
authors: Erohubie
authors: Bo
authors: B
authors: James
keywords: Antipsychotics; Defined daily dose; In-patients; Polypharmacy
references: J Clin Psychiatry. 1996;57 Suppl 11:84-8; discussion 89-93
references: 8941175
references: Int Psychiatry. 2009 Oct 01;6(4):96-98
references: 31508010
references: Int Clin Psychopharmacol. 2005 Nov;20(6):305-9
references: 16192838
references: Acta Psychiatr Scand. 1983 Aug;68(2):73-81
references: 6137939
references: Am J Psychiatry. 2004 Apr;161(4):700-6
references: 15056517
references: BMC Res Notes. 2008 Jun 12;1:25
references: 18710544
references: Int Clin Psychopharmacol. 2006 Nov;21(6):355-62
references: 17012982
references: Int Clin Psychopharmacol. 2008 Sep;23(5):287-90
references: 18703938
references: Br J Psychiatry. 1994 Jan;164(1):94-6
references: 7907925
references: Br J Clin Pharmacol. 2009 Jan;67(1):110-7
references: 19133060
references: Afr J Med Med Sci. 1995 Sep;24(3):261-7
references: 8798962
references: Br J Psychiatry. 2008 Jun;192(6):435-9
references: 18515893
references: Br J Psychiatry. 1994 Apr;164(4):448-58
references: 8038932
references: Hong Kong Med J. 2008 Feb;14(1):35-9
references: 18239241
references: Int Clin Psychopharmacol. 2007 Jul;22(4):221-5
references: 17519645